• Fludarabine-based reduced intensity transplantation with T depletion is safe and effective
Germline heterozygous GATA2 mutation causes failure of mononuclear cell development, immune dysfunction, and evolution to myeloid neoplasia [1] [2] [3] [4] . Symptoms may arise at almost any age, reaching a penetrance of 90% in the seventh decade 3 . Fatal complications include mycobacterial infection, uncontrolled herpesvirus infection, HPV-associated carcinoma and hematological transformation [1] [2] [3] [4] . Bone marrow transplantation is curative but the optimal timing and protocol remain undefined [4] [5] [6] [7] [8] [9] [10] [11] . Patients who developed GATA2-related MDS or AML have been successfully transplanted with myeloablative and reduced intensity conditioning, following standard clinical algorithms for hematological malignancy [2] [3] [4] . However, 21-60% of GATA2 patients do not present with MDS or AML 2, 3 and may suffer severe infectious complications, including significant pulmonary dysfunction. The optimal therapy for this group remains undefined 8, 9 .
Here we present a retrospective analysis of four patients, successfully transplanted with a T-cell depleted reduced intensity regimen for predominantly infectious and respiratory complications of GATA2 mutation. They include consecutive patients in our cohort transplanted at two UK centers, Manchester and Newcastle, with at least 2 years of follow up (2008) (2009) (2010) (2011) (2012) . Their laboratory indices have been previously described 2, 12, 13 and are summarized in Table S1 . Patients 1-3 had grossly elevated fms-like tyrosine kinase-3 (flt3) ligand and a severe DCML deficiency phenotype with relatively well preserved hemoglobin, neutrophils and platelets. Patient 4 had monocytopenia in the context of more conventional MDS with anemia, thrombocytopenia and mildly elevated flt3 ligand. GATA2 mutation and clinical features are summarized in Table 1 Transplantation is summarized in Table 1 . All patients received five doses of fludarabine 30mg/m 2 (day -7 to -3 or day -6 to -2) and an alkylating agent: melphalan 140mg/m 2 day -2; or busulfan IV 3.2mg/kg day -7 to -6; or treosulfan 14mg/m 2 day -6 to -4. Choice of alkykator reflected unit practice and was not patient-specific. In vivo T cell depletion with alemtuzumab was given at a total dose of 0.7 mg/kg to 1.2mg/kg in 2-5 divided doses. Mobilized PBSC grafts were infused at a dose of 1.9 -8.0 x10 6 CD34 + cells/kg supported with G-CSF from day +6. All patients received ciclosporin GVHD prophylaxis; Patients 1-3 with unrelated donors also received mycophenolate mofetil 1g twice daily for 30-60 days post transplant. All patients were discharged from hospital between 14 and 33 days post transplant. Three patients experienced grade I delayed acute GVHD (skin rash) during immunosuppression withdrawal but none required systemic therapy and none went on to develop chronic GVHD ( Table 1) . Patient 1 experienced an immune reconstitution syndrome of non-GVHD rash and fever in the first month, a common complication of BMT during active mycobacterial infection 15 , and required a short course of systemic corticosteroids. ITP was observed in patient 2 and haemolytic anaemia in patient 3, at 7 and 9 months post transplant, respectively. These complications are observed in other patients transplanted with fludarabine and Alemtuzumab-based conditioning and resolved within 4 weeks after initiation of treatment with Rituximab (375mg/m 2 per week for 4 weeks). High levels of myeloid and T cell chimerism were observed in all patients by three months (Figure 1B) . B cell chimerism was not routinely monitored. Patients 2-4 with significant respiratory compromise showed a marked and sustained improvement within weeks of transplant ( Figure 1C) . Continuous oxygen and non-invasive ventilation at night was rapidly withdrawn from patient 2 in association with dramatic radiological improvement ( Figure 1D) . Anti-mycobacterial drugs were discontinued posttransplant in patients 1 and 3, within 1 year, when CD3 T cells had increased above 200/µl. Patient 3 and his donor were both seropositive for CMV and a short reactivation was treated uneventfully with oral valganciclovir. The other 3 transplants were matched CMV negative. Patient 2 was vaccinated with bivalent HPV type 16/18 vaccine at 20, 21 and 26 months post-transplant and strikingly, her HPVassociated VIN III completely regressed by 36 months. She subsequently had two successful full-term pregnancies. Patient 1 was diagnosed with malignant melanoma 3 years after transplant but this was fully resected without further evidence of disease. All patients are alive between 4 and 8 years post-transplant with Karnofsky Performance Score 90-100%.
These cases illustrate that fludarabine-based reduced intensity transplantation with alemtuzuab in vivo T depletion is acceptable for patients with severe infectious and respiratory complications of GATA2 mutation. Alemtuzumab-based conditioning provided excellent control of graft versus host disease (GVHD) even with mismatched donors. Although it is surprising that GVHD occurs at all in the absence of recipient dendritic cells, monocytes and B cells, it has been reported as a lethal complication in other series 6, 8, 9, 11 . T cell depletion was not problematic and the rapid restoration of donor DCs, monocytes, B cells and NK cells led to a full recovery.
Life-threatening infection, severe respiratory compromise due to PAP, or both, were the major triggers for transplantation. In retrospect, it was discovered that 2 of the 4 patients had developed clonal hematopoiesis with ASXL1 mutation. Patients with both severe infection and myeloid neoplasia are especially challenging as reductions in conditioning intensity for infection-related co-morbidity may compromise the durability of remission from MDS or AML. Relapses were observed in a previously reported cohort following non-myeloablative conditioning with fludarabine and 2Gy total body irradiation 8 . Fludarabine combined with moderate dose alkylating agents, as employed here, has a track record in the transplantation of adults with MDS or AML 16, 17 . Our results suggest that this approach is a useful compromise for patients with uncontrolled infection and clonal hematopoiesis or early MDS. In females of reproductive age, fertility may already be compromised by pre-term labor and cervical or vulval intra-epithelial neoplasia 2 . Transplantation may indeed improve these prospects, as in the case of patient 2.
In summarizing this experience, we propose that life-threatening complications of GATA2-related disease including PAP, atypical mycobacterial infection and advanced HPV-associated dysplasia should be considered indications for transplantation, even in the absence of overt myeloid neoplasia. PAP responds poorly to conventional therapy with whole lung lavage and GM-CSF 18 , but resolves within weeks of transplantation 5 . Recurrent mycobacterial infection may exacerbate respiratory decline beyond the point of salvage if immune reconstitution is not provided. HPV-related intra-epithelial neoplasia can lead to disfiguring surgery which may prove ineffective at preventing lethal metastatic disease 9 . Detection of the accessory cellular phenotype of DCML deficiency is critical in identifying these patients, who present to a wide range of specialist services but rarely to hematooncology 12 . Once identified, thorough hematological evaluation is mandatory to exclude myeloid neoplasia and annual BM surveillance for clonal evolution is prudent. Finally, owing to the highly variable nature of GATA-2 associated syndromes, it is unlikely that a single approach to transplantation will suit all patients. 
